Author
Kyo Young Song
Other affiliations: St Mary's Hospital
Bio: Kyo Young Song is an academic researcher from Catholic University of Korea. The author has contributed to research in topics: Gastrectomy & Cancer. The author has an hindex of 34, co-authored 161 publications receiving 5054 citations. Previous affiliations of Kyo Young Song include St Mary's Hospital.
Topics: Gastrectomy, Cancer, Early Gastric Cancer, Survival rate, Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is concluded that this trial is safe and is thus ongoing, and there was no significance difference in the morbidity and mortality between the 2 groups.
Abstract: Objective The aim of this study was to evaluate the safety of this trial with respect to morbidity and mortality. Summary background data Laparoscopic-assisted distal gastrectomy (LADG) is rapidly gaining popularity. However, there is limited evidence regarding its oncologic safety. We therefore conducted a phase III multicenter, prospective, randomized study comparing LADG with open gastrectomy (ODG). Methods Patient eligibility criteria were pathologically-proven adenocarcinoma, 20 to 80 years of age, preoperative stage I, no history of other cancer, chemotherapy, or radiotherapy. The primary end point was to determine whether there is a difference in overall survival between 2 groups. The morbidity and mortality were compared to evaluate the safety of this trial. The time was decided on the hypothesis that the morbidity of this trial was not significantly different from that of previous reports on open gastric cancer surgeries (17%-20%). This study is registered at ClinicalTrials.gov and carries the following ID number: NCT00452751. Results A total of 342 patients were randomized (LADG, 179 patients; ODG, 161 patients) between January 1, 2006 and July 19, 2007. There were no significant differences between the 2 groups in age, gender, and comorbidities. The postoperative complication rates of the LADG and ODG groups were 10.5% (17/179) and 14.7% (24/163), respectively (P = 0.137). Reoperations were required in 3 cases each group. The postoperative mortality was 1.1% (2/179) and 0% (0/163) in the LADG and ODG groups (P = 0.497), respectively. Conclusion There was no significance difference in the morbidity and mortality between the 2 groups. Therefore, we conclude that this trial is safe and is thus ongoing.
695 citations
••
TL;DR: LADG for patients with clinical stage I gastric cancer is safe and has a benefit of lower occurrence of wound complication compared with conventional ODG.
Abstract: Objective:To determine the safety of laparoscopy-assisted distal gastrectomy (LADG) compared with open distal gastrectomy (ODG) in patients with clinical stage I gastric cancer in Korea.Background:There is still a lack of large-scale, multicenter randomized trials regarding the safety of LADG.Method
467 citations
••
TL;DR: This study demonstrates better survival for GC patients in Korea compared with the US as determined by multivariate analysis with a validated gastric cancer nomogram.
Abstract: Objective:To compare disease-specific survival (DSS) between the US and Korea following R0 resection for gastric carcinoma (GC).Summary Background Data:Many studies have described decreased 5-year survival after curative gastrectomy for GC in the West compared with the East. Although clinicopatholog
318 citations
••
Seoul National University Bundang Hospital1, Ajou University2, Dong-a University3, Catholic University of Korea4, New Generation University College5, Keimyung University6, Soonchunhyang University7, Chonbuk National University8, Chungnam National University9, Chonnam National University10, Ewha Womans University11, Yonsei University12
TL;DR: The KLASS-01 trial revealed similar overall and cancer-specific survival rates between patients receiving laparoscopic and open distal gastrectomy, and confirmed Laparoscopic distal Gastrointestinal Surgery is an oncologically safe alternative to open surgery for stage I gastric cancer.
Abstract: Importance Laparoscopic distal gastrectomy is gaining popularity over open distal gastrectomy for gastric cancer because of better early postoperative outcomes. However, to our knowledge, no studies have proved whether laparoscopic distal gastrectomy is oncologically equivalent to open distal gastrectomy. Objective To examine whether the long-term survival among patients with stage I gastric cancer undergoing laparoscopic distal gastrectomy is noninferior to that among patients undergoing open distal gastrectomy. Design The Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) group, which includes 15 surgeons from 13 institutes, conducted a phase 3, multicenter, open-label, noninferiority, prospective randomized clinical trial (KLASS-01) of patients with histologically proven, preoperative clinical stage I gastric adenocarcinoma from January 5, 2006, to August 23, 2010. Survival and recurrence status of the patients was determined in December 2016. Interventions Patients were randomly assigned (1:1) to laparoscopic distal gastrectomy (n = 705) or open distal gastrectomy (n = 711). Of these patients, 85 received a surgical approach opposite the one to which they were randomized (63 randomized to the open surgery group and 22 to the laparoscopic group). Main Outcomes and Measures Difference in 5-year overall survival between the laparoscopic and open distal gastrectomy groups. The noninferiority margin was prespecified as −5% (corresponding hazard ratio of 1.54), with an assumed survival of 90% after 5 years in the open surgery group. Results Among the 1416 patients (mean [SD] age, 57.3 [11.1] years; 940 [66.4%] male) included in the study, the 5-year overall survival rates were 94.2% in the laparoscopic group and 93.3% in the open surgery group (log-rankP = .64). Intention-to-treat analysis confirmed the noninferiority of the laparoscopic approach compared with the open approach (difference, 0.9 percentage points; 1-sided 97.5% CI, −1.6 to infinity). The 5-year cancer-specific survival rates were similar between the 2 groups (97.1% in the laparoscopic group and 97.2% in the open surgery group, log-rankP = .91; difference, −0.03 percentage points; 1-sided 97.5% CI, −1.8 to infinity). Per-protocol analysis results were consistent with the intention-to-treat results for overall and cancer-specific survival rates. Conclusions and Relevance The KLASS-01 trial revealed similar overall and cancer-specific survival rates between patients receiving laparoscopic and open distal gastrectomy. Laparoscopic distal gastrectomy is an oncologically safe alternative to open surgery for stage I gastric cancer. Trial Registration ClinicalTrials.gov identifier:NCT00452751
290 citations
••
TL;DR: The analysis of perioperative surgical outcomes indicated that robotic Gastrectomy is not superior to laparoscopic gastrectomy, and the use of robotic systems is assumed to provide a technically superior operative environment for minimally invasive surgery.
Abstract: Objective:To compare short-term surgical outcomes including financial cost of robotic and laparoscopic gastrectomy.Background:Despite a lack of supporting evidence, robotic surgery has been increasingly adopted as a minimally invasive modality for the treatment of gastric cancer because of its assum
216 citations
Cited by
More filters
•
3,097 citations
••
TL;DR: Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be considered as a treatment option for patients with operable gastric cancer.
1,286 citations
••
Klinikum St. Georg1, Vita-Salute San Raffaele University2, Montreal General Hospital3, Fujita Health University4, University Hospital of Lausanne5, Memorial Hospital of South Bend6, Sapienza University of Rome7, Örebro University8, National Institute for Health Research9, Oregon Health & Science University10, University of São Paulo11, University of Hohenheim12, Rabin Medical Center13
TL;DR: The focus of this guideline is to cover nutritional aspects of the Enhanced Recovery After Surgery (ERAS) concept and the special nutritional needs of patients undergoing major surgery, e.g. for cancer, and of those developing severe complications despite best perioperative care.
1,096 citations
••
TL;DR: The Avastin in Gastric Cancer (AVAGAST) trial as discussed by the authors evaluated the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer.
Abstract: Purpose The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized, placebo-controlled trial designed to evaluate the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer. Patients and Methods Patients received bevacizumab 7.5 mg/kg or placebo followed by cisplatin 80 mg/m2 on day 1 plus capecitabine 1,000 mg/m2 twice daily for 14 days every 3 weeks. Fluorouracil was permitted in patients unable to take oral medications. Cisplatin was given for six cycles; capecitabine and bevacizumab were administered until disease progression or unacceptable toxicity. The primary end point was overall survival (OS). Log-rank test was used to test the OS difference. Results In all, 774 patients were enrolled; 387 were assigned to each treatment group (intention-to-treat population), and 517 deaths were observed. Median OS was 12.1 months with bevacizumab plus fluoropyrimidine-cisplatin and 10.1 months with placebo plus fluoropyrimidine-cisplati...
943 citations
••
University of North Carolina at Chapel Hill1, Cleveland Clinic2, University of Washington3, American Society of Clinical Oncology4, BC Cancer Agency5, University of Granada6, Dartmouth–Hitchcock Medical Center7, Penn State Cancer Institute8, Emory University9, University of Rochester10, University College London11, McMaster University12, University of Southern California13, University of California, San Francisco14, Fred Hutchinson Cancer Research Center15, University of Milan16
TL;DR: An Expert Panel convened an Expert Panel to review the evidence and revise previous recommendations as needed to provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.
Abstract: PURPOSETo provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.METHODSPubMed and the Cochrane Library were searched for randomized...
900 citations